Endotoxin detection is an integral part of the quality control process, but it can prove challenging. For example, Low Endotoxin Recovery (LER) is a common and complicated phenomenon that can severely impact the reliability of results, which can result in risks to patient safety and noncompliance with regulations. The validation of new methods to address endotoxin testing obstacles often becomes an additional workload for teams to manage.
Did you know you can partner with our ENDOXPERTS™ team to establish a robust, reliable, and compliant endotoxin testing strategy for your products? At ENDOXPERTS™, we take the guesswork out of endotoxin detection. Our team of specialists supports you without draining your precious internal resources:
- Conducting feasibility studies for recombinant Factor C (rFC)-based methods
- Developing custom demasking strategies
- Ensuring regulatory-compliant workflows for biologics and biosimilars
Whether you're dealing with Low Endotoxin Recovery (LER) or struggling with matrix-related interferences, we design tailored demasking strategies and testing conditions that suit your product’s unique profile. For biologics in particular, where regulatory expectations can be especially complex, having a team of experts on your side can make the difference between delay and success.
With advanced technologies like ENDO-RS® and ENDOLISA®, we go beyond conventional methods to offer reproducible and sensitive solutions, even for the most interference-prone matrices. And we don’t stop at method development: we offer interpretation support, troubleshooting, and training to ensure your lab runs smoothly and your team stays focused on high-impact tasks.
At ENDOXPERTS™, we don’t just deliver methods: we deliver peace of mind.
Please consult:
- Our website for more information.
- Your local bioMérieux representative for ENDOXPERTS™ availability in your country
